- Home
- TGHL vs CYCN Comparison
TGHL vs CYCN Comparison
Compare TGHL & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | CYCN |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 16.6M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TGHL | CYCN |
|---|---|---|
| Price | $0.86 | $23.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 272.6K | 95.1K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $0.27 | $1.03 |
| 52 Week High | $2.48 | $8.48 |
Technical Indicators
Market Signals| Indicator | TGHL | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 41.06 |
| Support Level | $0.33 | $3.04 |
| Resistance Level | $0.95 | $3.42 |
| Average True Range (ATR) | 0.07 | 0.49 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 44.33 | 23.67 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.